What Pathway Labs does

Pathway Labs is a privately held, U.S.-based healthcare AI company whose core product, EchoNext, is an FDA-cleared (510(k), June 22, 2026) deep learning system that analyzes standard 12-lead electrocardiograms to identify patients likely to have structural heart disease, including LV and RV systolic dysfunction, aortic and mitral regurgitation, aortic stenosis, tricuspid and pulmonic regurgitation, severe LV hypertrophy, pulmonary hypertension, and pericardial effusion. The platform ingests existing ECG waveforms without requiring new hardware, runs AI inference enterprise-wide with routing to individual physicians and clinical champions, and embeds results into existing cardiology workflows to coordinate diagnosis and treatment for high-risk patients. The company has deployed EchoNext at 20 hospitals and tested 500,000+ patients, reporting a 91% increase in new clinically significant diagnoses, and its Nature 2025 paper is the most-read cardiac AI paper of all time.

The company operates a B2B enterprise licensing model targeting health systems, cardiology departments, and primary care, with direct field sales driven through a website-based partnership inquiry form and no publicly disclosed pricing. Pathway Labs raised $8.5 million in funding in June 2026 from AlleyCorp and Breyer Capital to expand deployment, and on the same day as FDA clearance announced a partnership with OpenEvidence to broaden distribution across health systems. Underlying scientific credibility is reinforced by peer-reviewed publications across Nature, Nature Medicine, NEJM AI, JACC, European Heart Journal, JAMA, and Circulation.

Name

Pathway Labs

Legal name

Pathway Labs

Website

https://pathwaylabs.com

Company type

Private

Operating status

Operating

Short description

Pathway Labs develops EchoNext, an FDA-cleared AI tool that analyzes standard 12-lead ECGs to detect structural heart disease early. It licenses the platform to health systems and has deployed across 20 hospitals with 500K+ patients tested.

Ownership category

akta.pro rank

Product category

AI Cardiac Diagnostics Software

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT) (HLAHAFAI)

akta.pro secondary industries

Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays (HLAAALAN), Chronic Disease Management Pathways (e.g., diabetes, CHF, COPD) (HLACAGAG)

Keywords

• AI cardiac diagnostics
• ECG analysis software
• Structural heart disease detection
• Clinical decision support
• Healthcare AI platform

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Enterprise Healthcare Licensing: B2B licensing model targeting health systems for deployment of EchoNext AI tool. Health systems initiate contact through partnership inquiry form. Pricing not publicly disclosed, suggesting enterprise quote-based model.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Pathway Labs develops and sells EchoNext, an FDA-cleared AI tool that analyzes standard 12-lead ECG data to detect hidden structural heart disease and surface high-risk patients for follow-up. It is deployed at the enterprise level across health systems without requiring new hardware, with AI inference, physician routing, and care coordination built into existing cardiology workflows.

Product overview

Pathway Labs offers a single unified product, EchoNext, an FDA-cleared AI system that detects structural heart disease from standard 12-lead ECGs. The system works by receiving standard ECG data, running AI inference instantaneously across health systems, and routing results to individual physicians and care teams. EchoNext enables centralized coordination to ensure high-risk patients receive diagnosis and treatment, with no hardware changes required.

Differentiator

Problem solved

Functional benefit

Brands

• EchoNext: AI-powered cardiac biomarker tool that reads standard 12-lead ECGs to detect structural heart disease including LV systolic dysfunction, RV systolic dysfunction, aortic stenosis, aortic regurgitation, mitral regurgitation, tricuspid regurgitation, pulmonic regurgitation, severe left ventricular hypertrophy, pulmonary hypertension, and pericardial effusion.

Products and services

• EchoNext FDA-cleared AI tool that reads standard 12-lead ECGs to detect structural heart disease, including LV systolic dysfunction, RV systolic dysfunction, aortic stenosis, aortic regurgitation, mitral regurgitation, tricuspid regurgitation, pulmonic regurgitation, severe left ventricular hypertrophy, pulmonary hypertension, and pericardial effusion. Deployed at the enterprise level across health systems, routing AI-inferred results to individual physicians and system champions with minimal IT integration and no new hardware required. Targeted at health systems, cardiology departments, and primary care.

Quantifiable outcome

• 91% increase in new clinically significant diagnoses
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Partnerships

Two partnerships are on record, tiered core and minor.

• OpenEvidencecoreTechnology or Integration · 22 June 2026Pathway Labs is partnering with OpenEvidence to expand EchoNext into more health systems. OpenEvidence is an AI-powered medical information platform. The partnership enables broader distribution and integration of the cardiac AI diagnostic tool across healthcare networks.
• Press and Media PartnersminorGTM or Marketing PartnerFeatured and covered by leading medical and general news outlets including Nature, The New York Times, NEJM AI, Nature Medicine, JACC, JAMA, European Heart Journal, Circulation, Reuters, STAT, CNN, and Becker's Hospital Review.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Anumana: Anumana (Mayo Clinic Platform spinout) develops AI algorithms applied to ECG signals to detect cardiac conditions including structural heart disease, making it a direct clinical and technical peer to EchoNext.
• HeartFlow: HeartFlow provides AI-based FFR-CT analysis for coronary disease and is now expanding into broader structural heart assessment; comparable in regulatory pathway, evidence strategy, and health-system commercial model.
• Ultromics: Ultromics develops AI-based echocardiography analysis to support diagnosis of conditions including heart failure and valve disease, making it a direct clinical peer focused on the same structural-heart detection Pathway targets.
• Eko Health: Eko Health combines connected stethoscopes and digital ECG devices with AI cardiac analysis (SENSORA) for clinicians, overlapping directly with EchoNext on AI-driven cardiac detection from standard ECG inputs.
• AliveCor: AliveCor (KardiaMobile/KardiaStation) builds FDA-cleared AI that interprets consumer and clinical ECGs for arrhythmias; it is the closest direct competitor to EchoNext's AI-on-ECG positioning, with overlap in health-system enterprise deployment.
• Idoven: Idoven offers an AI cloud platform that analyses continuous ambulatory ECG data to surface cardiac arrhythmias and structural abnormalities, closely comparable in technology and target customer base to EchoNext.
• Cleerly: Cleerly applies AI to cardiac CT angiography to identify coronary artery disease; it is a peer in AI-driven cardiac diagnostics with overlapping health-system enterprise buyers and a similar reimbursement/clinical-evidence narrative.
• Caption Health (GE HealthCare): Caption Health (acquired by GE HealthCare) provides FDA-cleared AI for cardiac ultrasound interpretation; it is a direct peer in the AI-enabled cardiac diagnostics category that health systems buy alongside EchoNext.

Broad incumbents

• GE HealthCare: GE HealthCare is a broad incumbent in cardiac diagnostics and imaging, now including Caption Health AI; it competes for ECG and echo AI budgets and could bundle competing structural-heart AI capabilities into its enterprise contracts.
• Tempus Labs: Tempus is a large AI-driven precision medicine platform with growing cardiovascular offerings; it competes for the same enterprise health-system AI budgets and clinical leadership attention as Pathway Labs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pathway Labs